University of Cincinnati Department of Pediatrics

Timothy P. Cripe, MD, PhD

Title

Co-Medical Director, Office for Clinical and Translational Research

Director of Pilot and Collaborative Studies, Center for Clinical & Translational Research and Training

Appointment

Professor of Pediatrics - Affiliated, University of Cincinnati College of Medicine

Email

timothy.cripe@cchmc.org

Phone

513-636-4553

Fax

513-636-7066

Bio

Timothy P. Cripe, MD, PhD, graduated Magna Cum Laude from Princeton University with a degree in Biochemistry. He completed his MD, PhD in genetics, and pediatric residency training at the University of Iowa.

Dr. Cripe was a clinical fellow in pediatric hematology/oncology at the Children's Hospital and the Dana-Farber Cancer Institute in Boston, affiliate institutions of Harvard medical School, and a research fellow at the Children's Hospital and University of Colorado Health Sciences Center in Denver. Following his subspecialty training, Dr. Cripe was an Assistant Professor of Pediatrics at the University of Wisconsin Children's Hospital and Comprehensive Cancer Center in Madison and was the Medical Director of the UW/ American Red Cross Hemophilia Treatment Center.

Dr. Cripe and his wife, a pediatric cardiologist, have three children.

Credentials

AB: Princeton University, Princeton, NJ, 1982.

MD, PhD: University of Iowa, Iowa City, IA, 1989.

Residency: Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA, 1989-1992.

Fellowship: Dana-Farber Cancer Institute/ Children's Hospital, Boston, MA, 1992-1993; University of Colorado Health Sciences Center/Children's Hospital, Denver, CO, 1993-1995.

Certification: Diplomate, American Board of Pediatrics, 1993; Pediatric Hematology / Oncology, 1996.

Awards and Honors

Awarded, Best Doctors in America, 2008

Research

Transcriptional regulation; genetic perturbations in cancer; gene therapy of cancer; gene transfer; transcriptional targeting; antiangiogenesis; viral oncolysis; viral oncogenesis

Cripe Lab

Our primary mission and interest is the development of new therapies for cancer based on a platform of oncolytic viruses.

Research Grants and Contracts

NIH P50 NS057531-01A1 Cincinnati Center for Neurofibromatosis (Ratner) 2008 - 2013, "Xenograft Core for NF1 Experimental Therapeutics"

NCI R21 CA133663-01A1 (Cripe) 2008 - 2010, "Targeted Virotherapy for Neuroblastoma Stem Cells"

Children's Tumor Foundation (Cripe - Center Director) 2008 - 2011, "NF1 Preclinical Testing Consortium"

Crusade Laboratories, Ltd., United Kingdom (Cripe) 2007 - 2008, "Nonclinical Laboratory Study Protocol: Bridging Studies of HSV1716 in Support of BB-IND 13196"

NIH-NCI, 1R01-CA114004-01A2 (Cripe) 2006 - 2011, "Oncolytic HSV Therapy in Immunocompetent Sarcoma Models"

NIH K30 HL078581 (Tsevat) 08/01/05-07/31/10, "University of Cincinnati Clinical Research Training"

Publications, Most Recent

Connect to Timothy Cripe's publications on PubMed

Johansson G, Mahller YY, Collins MH, Kim M-O, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma S, Thomas G, Ratner N. Effective in vivo targeting of the mTOR pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 7:1237-1245, 2008.

Currier MA, Gillespie RA, Sawtell NM, Mahler YY, Stroup G, Kambara H, Hildeman DA, Chiocca EA, Cripe TP. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 16:879-885, 2008.

Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP. Tissue inhibitor of metalloproteinase-3 via oncolytic herpes virus inhibits tumor growth and vascular progenitors. Cancer Res 68:1170-1179, 2008.

Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu Y-H, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP. Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model. Mol Ther 15:279-286, 2007.

Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB, Uren A. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 66:5574-81, 2006.

Mahller YY, Rangwala F, Ratner N, Cripe TP. Malignant Peripheral Nerve Sheath Tumors with High and Low Ras are Permissive for Oncolytic Herpes Simplex Virus Mutants. Ped Blood Cancer
46:745-754, 2006.

Applebaum H, Kieran MW, Cripe TP, Coffin CM, Collins MH, Kaipainen A, Laforme A, Shamberger RC. The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg. 2005 Jun;40(6):999-1003; discussion 1003.

Cripe TP, Thomson B, Boat TF, Williams DA. Promoting translational research in academic health centers: navigating the "roadmap". Acad Med. 2005 Nov;80(11):1012-8.

Parikh N, Currier MA, Adams LC, Mahller, YY, DiPasquale B, Collins MH, Cripe TP. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer. 2005 May;44(5):469-78.

Currier M, Mahller L, Adams L, Cripe T. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther. 2005 Apr;12(4):407-16.

Parikh N, Hoyer J, Cripe T. A young girl with hemolytic anemia and elevated hemoglobin F. Pediatr Blood Cancer. 2005 Mar;44(3):264-6.

Halsted MJ, Perry LA, Cripe TP, Collins MH, Jakobovits R, Benton C, Halsted DG. Improving patient care: the use of a digital teaching file to enhance clinicians' access to the intellectual capital of interdepartmental conferences. AJR Am J Roentgenol. 2004 Feb;182(2):307-9. Review.

Dickens DS and Cripe TP. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol. 2003 Sep;25(9):709-14.

Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003 Apr;25(4):282-5.

Editing:

2008-present: Member, Editorial Board, Gene Therapy.

2008-present: Member, Editorial Board, Molecular Therapy.

1999-present: Managing Editor for Pediatric Oncology Section, eMedicine Journal.

Presentations, Most Recent

Invited Speaker, "Non-CNS Pediatric Solid Tumor Targets of Oncolytic HSV." Cincinnati Children's Hospital Medical Center, HSV Symposium, Cincinnati, Ohio, September 2008.

Invited Speaker, "Preclinical and Clinical Development of Oncolytic Virotherapy at CCHMC." Pediatric Oncology Program Retreat, Ohio State University Comprehensive Cancer Center, Wilmington, Ohio, September 2008.

Invited Speaker, "Targeting Oncolytic Herpes Virotherapy to Cancer Initiating Cells." Noon Research Conference, Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, August 2008.

Invited Speaker, "Challenges and Opportunities of Pediatric Translational Research." Grand Rounds, Arkansas Children's Hospital, Little Rock, Arkansas, August 2008.

Invited Speaker, "Cancer Virotherapy." Immunohematology Seminar Series, Cincinnati Children's Hospital, Cincinnati, Ohio, March 2008.

Invited Speaker, "Translational Research Initiative Grants Program 2008." Departmental Faculty Meeting, Cincinnati Children's Hospital, Cincinnati, Ohio, March 2008.

Invited Speaker, "Can Oncolytic Viruses Be Used to Treat Metastatic Disease?" Divisional Translational Research Retreat, Kingsgate Marriott, Cincinnati, Ohio, March 2008.

Invited Speaker, "Targeted Experimental Therapeutics for Pediatric Solid Tumors." Fellow Lecture: DataBlitz, Cincinnati Children's Hospital, Cincinnati, Ohio, February 2008.

Invited Speaker, "Neurofibromatosis Preclinical Consortium: Cincinnati Site." Children's Tumor Foundation Director's Meeting, Newark, New Jersey, January 2008.

Invited Speaker, "Excitements and Challenges of Identifying, Enhancing and Translating Targeted Biotherapeutics for Pediatric Cancers." National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, November 2007.

Invited Speaker, "Got Herpes? Developing Oncolytic Virus Therapy for Pediatric Cancer." Van Andel Research Institute, Grand Rapids, Michigan, November 2007.

Invited Speaker, "Therapeutic Targeting of Neuroblastoma Stem Cells with Oncolytic HSV." Tumor Biology Nidus Group, Cincinnati Children's Hospital, Cincinnati, Ohio, October 2007.

Invited Speaker, "Safety and Toxicology Studies of Oncolytic HSVs." Vector Club, Cincinnati Children's Hospital, Cincinnati, Ohio, October 2007.

Invited Speaker, "Translational Research Initiative Grants Program 2008." Departmental Faculty Meeting, Cincinnati Children's Hospital, Cincinnati, Ohio, September 2007.

Invited Speaker, "Targeted Experimental Therapeutics for Pediatric Solid Tumors." Fellow Lecture: DataBlitz, Cincinnati Children's Hospital, Cincinnati, Ohio, August 2007.

Invited Speaker, "Translational Research Initiative Grants Program 2008." Division Chefs Meeting, Cincinnati Children's Hospital, Cincinnati, Ohio, August 2007.

Invited Speaker, "Masters in Clinical Research: The Translational Track." Masters in Clinical Research Program Orientation, University of Cincinnati, Cincinnati, Ohio, June 2007.

Invited Speaker, "TIMP3 Gene Therapy Causes Tumor Antiangiogenesis." Vascular Club, Cincinnati Children's Hospital, Cincinnati, Ohio, May 2007.

Invited Speaker, "TRTO: An Institutional Core Created by the Divisions of Experimental Hematology and Hematology/Oncology." Divisional Scientific Advisory Committee External Review, Cincinnati Children's Hospital, March 2007.

Invited Speaker, "Oncolytic HSV Replication in Explant Tissue Cores Correlates with In Vivo Tumor Response in Xenograft Cancer Models." Fourth International Conference on Virus Therapy for Cancer, Phoenix, Arizona, March 2007.

Professional Organization Memberships

2004-present: Member, Soft Tissue Sarcoma Committee, Children's Oncology Group
2000 - present: Member, Children's Oncology Group
2000 - 2004: Member, European Society of Gene Therapy
2000 - present: Member, American Society of Gene Therapy
1999 - present: Member, American Association for Cancer Research
1995 - present: Member, Association for the Advancement of Science
1995 - present: Member, American Society of Pediatric Hematology / Oncology
1994 - 2005: Member, American Society of Hematology
2007 - present: Member, American Pediatric Society
2005 - present: Member, Connective Tissue Oncology Society
2004 - present: Member, Society for Pediatric Research